Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Current Hematologic Malignancy Reports|February 22, 2015
Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitorsChristopher A Eide, Thomas O'Hare
Nature Medicine|June 7, 2017
Understanding cancer from the stem cells upChristopher A Eide, Brian J Druker
Oncotarget|August 13, 2013
Kinase inhibitor therapy in CML: it's what's inside that countsChristopher A Eide, Brian J Druker, Thomas O'Hare
Expert Opinion on Investigational Drugs|May 22, 2008
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkThomas O'Hare, Christopher A Eide, Michael W Deininger
Journal of the National Cancer Institute|June 26, 2008
Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Clinical Lymphoma & Myeloma|March 27, 2007
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Blood|May 15, 2007
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W N Deininger
Cancer Cell|April 15, 2020
Response and Resistance to BCR-ABL1-Targeted TherapiesTheodore P Braun, Christopher A Eide, Brian J Druker
Clinical Lymphoma & Myeloma|March 4, 2009
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?Jennifer L Snead, Thomas O'Hare, Christopher A Eide, et al.
Blood|September 25, 2013
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemiaVladimir Vainstein, Christopher A Eide, Thomas O'Hare, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Current Hematologic Malignancy Reports|February 22, 2015
Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitorsChristopher A Eide, Thomas O'Hare
Nature Medicine|June 7, 2017
Understanding cancer from the stem cells upChristopher A Eide, Brian J Druker
Oncotarget|August 13, 2013
Kinase inhibitor therapy in CML: it's what's inside that countsChristopher A Eide, Brian J Druker, Thomas O'Hare
Expert Opinion on Investigational Drugs|May 22, 2008
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkThomas O'Hare, Christopher A Eide, Michael W Deininger
Journal of the National Cancer Institute|June 26, 2008
Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Clinical Lymphoma & Myeloma|March 27, 2007
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Blood|May 15, 2007
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W N Deininger
Cancer Cell|April 15, 2020
Response and Resistance to BCR-ABL1-Targeted TherapiesTheodore P Braun, Christopher A Eide, Brian J Druker
Clinical Lymphoma & Myeloma|March 4, 2009
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?Jennifer L Snead, Thomas O'Hare, Christopher A Eide, et al.
Blood|September 25, 2013
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemiaVladimir Vainstein, Christopher A Eide, Thomas O'Hare, et al.
Pageof 9